288 related articles for article (PubMed ID: 21839418)
1. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions.
Grutters JP; Seferina SC; Tjan-Heijnen VC; van Kampen RJ; Goettsch WG; Joore MA
Value Health; 2011; 14(5):777-84. PubMed ID: 21839418
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
Norum J
Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
[TBL] [Abstract][Full Text] [Related]
3. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
5. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
6. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
[TBL] [Abstract][Full Text] [Related]
7. Differences between systematic reviews and health technology assessments: a trade-off between the ideals of scientific rigor and the realities of policy making.
Rotstein D; Laupacis A
Int J Technol Assess Health Care; 2004; 20(2):177-83. PubMed ID: 15209177
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
10. Costly cancer drugs trigger proposals to modify clinical trial design.
Schmidt C
J Natl Cancer Inst; 2009 Dec; 101(24):1662-4. PubMed ID: 19933943
[No Abstract] [Full Text] [Related]
11. Do economic evaluations of targeted therapy provide support for decision makers?
Ferrusi IL; Leighl NB; Kulin NA; Marshall DA
Am J Manag Care; 2011 May; 17 Suppl 5 Developing(0 5 0):SP61-70. PubMed ID: 21711079
[TBL] [Abstract][Full Text] [Related]
12. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
13. [Health economics and HTA].
Kulp W; Greiner W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
Simoens S
Pharmacoeconomics; 2007; 25(3):181-5. PubMed ID: 17335304
[No Abstract] [Full Text] [Related]
15. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?
Garattini L; van de Vooren K; Curto A
Health Policy; 2015 Feb; 119(2):212-6. PubMed ID: 25523144
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab for early breast cancer: evolution or revolution?
Littlejohns P
Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
[No Abstract] [Full Text] [Related]
18. Considerations for transferability of health technology assessments: a scoping review of tools, methods, and practices.
Heupink LF; Peacocke EF; Sæterdal I; Chola L; Frønsdal K
Int J Technol Assess Health Care; 2022 Nov; 38(1):e78. PubMed ID: 36321421
[TBL] [Abstract][Full Text] [Related]
19. Are adverse effects incorporated in economic models? An initial review of current practice.
Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
[TBL] [Abstract][Full Text] [Related]
20. Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers.
Pichon-Riviere A; Augustovski F; García Martí S; Sullivan SD; Drummond M
Int J Technol Assess Health Care; 2012 Apr; 28(2):180-6. PubMed ID: 22559762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
